Algos, Cambridge NeuroScience deal

CNSI received a non-exclusive license to three ALGO patents covering the use of NMDA ion channel blockers to treat pain either as monotherapy or in combination with other treatments. In exchange, ALGO received first rights to negotiate to develop and/or commercialize any CNSI products covered by the patents, including the company's CNSI 5161 NMDA ion channel blocker, which has completed Phase I testing to treat pain. ...